Analysts: Generics could hamper Novo Nordisk's business in China
Novo Nordisk could lose billions of kroner in revenue when the Danish pharmaceutical companys molecule Semaglutide - which is the active ingredient in the obesity drug Wegovy as well as the diabetes drug Ozempic - goes off patent in 2026 in China.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.